915213-24-0Relevant articles and documents
P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS
-
Paragraph 0224; 0225, (2015/07/07)
The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.
The effect of pKa on pyrimidine/pyridine-derived histamine H4 ligands
Savall, Brad M.,Meduna, Steven P.,Venable, Jennifer,Wei, Jianmei,Smith, Russell C.,Hack, Michael D.,Thurmond, Robin L.,McGovern, Patricia,Edwards, James P.
, p. 5489 - 5492 (2015/01/08)
During the course of our efforts toward the discovery of human histamine H4 antagonists from a series of 2-aminiopyrimidines, it was noted that a 6-trifluoromethyl group dramatically reduced affinity of the series toward the histamine H4 receptor. This observation was further investigated by synthesizing a series of ligands that varied in pKa of the pyrimidine derived H4 ligands by over five orders of magnitude and the effect on histamine H4 affinity. This trend was then extended to the discovery of C-linked piperidinyl-2-amino pyridines as histamine H4 receptor antagonists.
ARYL-QUINOLINE DERIVATIVES
-
Paragraph 0530; 0531, (2013/05/21)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
NEW ARYL-QUINOLINE DERIVATIVES
-
Page/Page column 84-85, (2013/05/22)
The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.
Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
-
Page/Page column 43, (2008/06/13)
A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
